Esperion Therapeutics Total Current Liabilities

As of the most recent data (March 2026), ESPR shows a total current liabilities of $300M. That compares with $270M in the prior-year period — up 10.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ESPR's total current liabilities is now $300M (was $270M) — a 10.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Esperion Therapeutics is outperforming or lagging.

Tracking ESPR's total current liabilities over time shows whether Esperion Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $300M That compares with $270M in the prior-year period — up 10.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Esperion Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $300M) with ownership activity and broader fundamentals.

Esperion Therapeutics's total current liabilities is $300M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.